Yesterday, ETC Group reported on the scheduled meeting of Brazil's Judicial Commission to rule on the constitutionality of a bill that would allow the planting of Terminator plants (i.e., plants engineered to be sterile in the second generation) in Brazil. While the Judicial Commission did meet, it postponed the discussion on the Terminator bill until next week.
Kathy Jo Wetter's blog
On January 15, 2008, these two headlines shared the same Google News page. What's wrong with this picture?
"F.D.A. Says Cloned Animals Safe to Eat"
"188000 Pounds Of Tainted Beef Recalled"
On October 10, ETC Group attended the US Food and Drug Administrations first public meeting on nanotechnology. About 40 people had signed up to make presentations, and we were each given eight minutes to say our piece to the FDAs newly-formed Nanotechnology Task Force. (You can read the text of ETC Groups presentation here.)
The biotech company Ventria Biosciences sponsored tests, on babies and children hospitalized at two pediatric institutes in Peru, of two new experimental drugs derived from transgenic rice that was genetically engineered with synthetic human genes to produce artificial human milk proteins.
We've just read the article, "Lessons on Ethical Decision Making from the Bioscience Industry" - this is not a joke - which appeared in the May issue of PLoS Medicine and is available on the Internet. The authors are Jocelyn E. Mackie, Andrew D. Taylor, David L. Finegold, Abdallah S. Daar and Peter A. Singer. Four of the five authors are at the University of Toronto Joint Centre for Bioethics.
While some ETC Group staff were in Caracas strategizing with partners to strengthen the global opposition to Terminator, others of us were subjected to the slog of the CBD meeting in Granada. And one of us was spending a few days with unlimited access to free chocolate at Swiss Re's opulent Centre for Global Dialogue near Zurich. Swiss Re, the world's largest re-insurer (an insurer of insurance companies) is concerned - no surprise - about those risks associated with nanotechnology that may result in financial losses for the company.